NEJM: Moderate-intensity exercise + Liraglutide (3.0 mg/d)-teach you how to lose weight healthily!
Time of Update: 2021-11-13
Combining exercise and liraglutide treatment strategies can improve the maintenance of healthy weight loss .
1 mg can cause cancer. The test results of aflatoxin, an expired food, are amazing!
Time of Update: 2021-07-28
Vegetable oil that has been stored for a long time may produce a small amount of aflatoxin.
Severe muscle weakness (MG) new drug! The National Drug Administration grants and platinum medicine
Time of Update: 2021-03-03
binding to each other and accelerates the removal of IgG in the body, thus effectively treating autoimmune diseases mediated by pathogenic IgG. available evidence suggests that lower IgG levels in patients with severe muscle weakness (MG
Gastroenterology: Equsimod 2 mg or effective treatment for ulcerative colitis
Time of Update: 2020-12-16
, the results showed that in patients with moderate to severe active ulcerative colitis, 2 mg of equsimod improved clinical and endoscopic results.
Intercrystalline corrosion behavior of Mg, Ag, Zn microalloalized Al-Cu-Li aluminum lithium alloy T6-state esophpathy
Time of Update: 2020-11-07
(3) Mg-Ag microalloalized Al-Cu-Li aluminum lithium alloys exhibit intercrystalline corrosion morphological processes that differ from the other three alloys, representing local intercrystalline corrosion or comprehensive intercrystalline corrosion from olex to obsolescence, and pitting and accompanying intercrystalline corrosion at peak olescence.
Gastroenterology: 2 mg etremod is effective and safe for the treatment of ulcerative colitis.
Time of Update: 2020-10-11
, the results showed that in patients with moderate to severe active ulcerative colitis, equsimod 2 mg improved clinical and endoscopic results more effectively than placebo.
FDA approves for launch of Therapeutics MD's BIJUVA ™ capsule (1 mg/100 mg)
Time of Update: 2020-06-11
in line with FDA guidelines, the common primary therapeutic endpoint in this supplementary trial is a change in the value and severity of hot flashes in the 4th and 12th weeks in comparison to placebo.
Bayer company announced that it will carry out phase III clinical trial of new arbacicept 8 mg preparation
Time of Update: 2020-02-10
Bayer and regeneron pharmaceuticals, Inc
today announced that they will carry out two phase III studies, photon and pulsar, to assess the prolongation of the interval
First domestic PD-1 price announced, only 30 yuan / mg
Time of Update: 2019-01-08
On December 17, 2018, tuoyi, the first anti-PD-1 monoclonal antibody independently developed in China, was approved by the State Drug Administration for listing.